Macrocyclic peptidomimetic protease inhibitor and use thereof
US-2024327458-A1 · Oct 3, 2024 · US
Compositions comprising antibacterial agent and tazobactam
US10525043B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10525043-B2 |
| Application number | US-201114111627-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 1, 2011 |
| Priority date | May 28, 2011 |
| Publication date | Jan 7, 2020 |
| Grant date | Jan 7, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A pharmaceutical composition comprising antibacterial agent and tazobactam, wherein the ratio of tazobactam to the antibacterial agent in the composition is in the range of from about 0.5 to about 2 gram of tazobactam per gram of the antibacterial agent, are disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising active ingredients consisting of (a) cefepime or a pharmaceutically acceptable salt thereof; and (b) tazobactam or a pharmaceutically acceptable salt thereof, wherein the composition comprises 2 grams of cefepime and 2 grams of tazobactam, and is capable of treating bacterial infection in a subject. 2. The pharmaceutical composition according to claim 1 , wherein the tazobactam is present as tazobactam sodium. 3. The pharmaceutical composition according to claim 1 , wherein the composition is a powder or a solution.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antibacterial agents · CPC title
- A61K31/407Primary
condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems · CPC title
containing further heterocyclic rings, e.g. cephalothin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10525043B2 cover?
- A pharmaceutical composition comprising antibacterial agent and tazobactam, wherein the ratio of tazobactam to the antibacterial agent in the composition is in the range of from about 0.5 to about 2 gram of tazobactam per gram of the antibacterial agent, are disclosed.
- Who is the assignee on this patent?
- Bhagwat Sachin Subhash, Jafri Mohammad Alam, Patel Mahesh Vithalbhai, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/407. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).